REDWOOD CITY, Calif.--(BUSINESS WIRE)--Pheast Therapeutics, a clinical-stage biotechnology company advancing next-generation macrophage-directed immunotherapies for cancer, today announced it will host an educational webinar on Monday, August 10, 2026 from 12:00 p.m. – 2:00 p.m. ET. The webinar will focus on the emerging role of macrophage checkpoint biology for the treatment of solid tumors as well as Pheast’s lead program, PHST001, a novel, high-affinity IgG4 anti-CD24 monoclonal antibody curr